论文部分内容阅读
目的 研究以高剂量表阿霉素为主的联合化疗（ ＭＥＰ） 方案对晚期非小细胞肺癌的疗效和毒副反应。 方法 ２０ 例晚期非小细胞肺癌患者接受ＭＥＰ方案化疗：ＭＭＣ６ ｍｇ／ｍ２ ，ＥＰＩ１００ ｍｇ／ｍ２ ，ＤＤＰ７５ ～９０ ｍｇ／ｍ２ 。每个病例至少化疗２ 疗程。 结果 １ 例获ＣＲ，８ 例ＰＲ，总有效率（ＣＲ＋ ＰＲ）４５ ％ 。主要的毒副反应为白细胞下降、恶心和呕吐、脱发，多为Ⅰ、Ⅱ级，患者可以耐受。 结论 含高剂量表阿霉素的联合化疗方案对晚期非小细胞肺癌有较好的疗效，不良反应能耐受。
Objective To investigate the efficacy and toxicity of high-dose epirubicin-based combined chemotherapy (MEP) regimen for advanced non-small cell lung cancer. Methods 20 patients with advanced non-small cell lung cancer received MEP chemotherapy: MMC 6 mg/m2, EPI 100 mg/m2, and DDP 75 to 90 mg/m2. Each case was treated with at least 2 courses of chemotherapy. Results CR was obtained in 1 patient and PR in 8 patients. The total effective rate (CR+PR) was 45%. The major toxicities were leukopenia, nausea and vomiting, and hair loss, mostly grades I and II, and patients could tolerate it. Conclusion The combined chemotherapy regimen with high dose of epirubicin has good curative effect on advanced non-small cell lung cancer, and the adverse reactions can be tolerated.